| Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy | Nature Medicine | 2014 | 596 |
| Metabolic control of autophagy | Cell | 2014 | 591 |
| Consensus guidelines for the detection of immunogenic cell death | OncoImmunology | 2014 | 524 |
| Classification of current anticancer immunotherapies | Oncotarget | 2014 | 301 |
| A dual role for autophagy in a murine model of lung cancer | Nature Communications | 2014 | 296 |
| Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies | European Journal of Cancer | 2014 | 208 |
| Dendritic cell-derived exosomes as immunotherapies in the fight against cancer | Journal of Immunology | 2014 | 181 |
| Trial watch: IDO inhibitors in cancer therapy | OncoImmunology | 2014 | 166 |
| Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics | European Journal of Cancer | 2014 | 159 |
| Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling | Cell Death and Differentiation | 2014 | 152 |
| Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors | Annals of Oncology | 2014 | 133 |
| Chloroquine and hydroxychloroquine for cancer therapy | Molecular and Cellular Oncology | 2014 | 120 |
| Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases | European Journal of Cancer | 2014 | 106 |
| Prioritizing targets for precision cancer medicine | Annals of Oncology | 2014 | 106 |
| Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations | Blood | 2014 | 93 |
| Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study | European Journal of Cancer | 2014 | 86 |
| Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients | Médecine Et Maladies Infectieuses | 2014 | 83 |
| Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma | Cancer Research | 2014 | 79 |
| Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin | European Journal of Surgical Oncology | 2014 | 63 |
| Therapeutic drug monitoring in cancer--are we missing a trick? | European Journal of Cancer | 2014 | 62 |
| Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy | OncoImmunology | 2014 | 61 |
| New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response | European Respiratory Review | 2014 | 60 |
| Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study | Orphanet Journal of Rare Diseases | 2014 | 56 |
| Trial watch: Dendritic cell-based anticancer therapy | OncoImmunology | 2014 | 54 |
| A Randomized, Open-Label, Phase III Trial of Afatinib (A) Vs Erlotinib (E) As Second-Line Treatment of Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung Following First-Line Platinum-Based Chemotherapy: Lux-Lung 8 (Ll8) | Annals of Oncology | 2014 | 52 |
